Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/185464FILOVIRUS ANTIBODIES AND METHODS
WO 17.09.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2020/020982 Applicant STC.UNM Inventor DURVASULA, Ravi
An antibody that binds to a filovirus glycoprotein generally includes include a complementarity determining region (CDR) of any one of SEQ ID NO:27-36 or a combination of such CDRs. The antibody may be used in to detect filovirus in a biological sample obtained from a subject. The antibody also may be formulated into a pharmaceutical composition for administering to a subject having, or at risk of having, a filovirus infection.
2.20200282046BETACORONAVIRUS MRNA VACCINE
US 10.09.2020
Int.Class A61K 39/155
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
155Paramyxoviridae, e.g. parainfluenza virus
Appl.No 16880829 Applicant ModernaTX, Inc. Inventor Giuseppe Ciaramella

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

3.20200281953COMBINATION TUMOR IMMUNOTHERAPY
US 10.09.2020
Int.Class A61K 31/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
Appl.No 16867296 Applicant CHECKMATE PHARMACEUTICALS, INC Inventor Arthur Krieg

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

4.WO/2020/180700PROTEIN RESIDUE MAPPING USING A COMBINATION OF DEEP MUTATIONAL SCANNING AND PHAGE DISPLAY HIGH THROUGHPUT SEQUENCING
WO 10.09.2020
Int.Class C40B 40/08
CCHEMISTRY; METALLURGY
40COMBINATORIAL TECHNOLOGY
BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
40Libraries per se, e.g. arrays, mixtures
04Libraries containing only organic compounds
06Libraries containing nucleotides or polynucleotides, or derivatives thereof
08Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Appl.No PCT/US2020/020429 Applicant FRED HUTCHINSON CANCER RESEARCH CENTER Inventor OVERBAUGH, Julie
The current disclosure provides protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing. The disclosed methods allow mapping of antibody epitopes and determination of changes in residues of a protein that abolish binding of the protein to a candidate binding molecule.
5.20200277358ENGINEERED POLYPEPTIDES AND USES THEREOF
US 03.09.2020
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Appl.No 16845894 Applicant VISTERRA, INC. Inventor Karthik Viswanathan

Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

6.20200277359ANTIBODY-MEDIATED NEUTRALIZATION OF CHIKUNGUNYA VIRUS
US 03.09.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16598380 Applicant VANDERBILT UNIVERSITY Inventor James E. CROWE, Jr.

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

7.20200276325Immunoconjugates with an Intracellularly-Cleavable Linkage
US 03.09.2020
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No 16841345 Applicant Immunomedics, Inc. Inventor Serengulam V. Govindan

The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

8.WO/2020/173460FULL HUMAN BROAD-SPECTRUM NEUTRALIZING ANTIBODY 4F1 AGAINST RESPIRATORY SYNCYTIAL VIRUS AND USE THEREOF
WO 03.09.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2020/076767 Applicant SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES Inventor SUN, Bing
Disclosed are a full human broad-spectrum neutralizing antibody against respiratory syncytial virus and use thereof. Specifically, disclosed in the present invention are a full human monoclonal antibody 4F1 against a respiratory syncytial virus fusion protein (F protein) and pre-fusion F protein (preF protein), a nucleic acid sequence encoding said antibody and an antibody fragment, and a preparation method therefor. In vivo and in vitro experiments confirm that said 4F1 antibody can effectively prevent and control RSV infection, has low immunogenicity in the human body, can avoid immune rejection reactions mediated by heterogenetic antibodies such as human anti-mouse, and can be used clinically for preventing and treating respiratory syncytial virus infection.
9.111592594一种抗新型冠状病毒的单克隆抗体及其应用
CN 28.08.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202010177710.7 Applicant 北京大学 Inventor 谢晓亮
本发明涉及免疫学领域和分子病毒学领域,特别是新型冠状病毒的诊断、预防和治疗领域。具体而言,本发明涉及抗新型冠状病毒的单克隆抗体,以及包含所述抗体的组合物(例如,诊断剂和治疗剂)。此外,本发明还涉及所述抗体的用途。本发明的抗体可用于诊断、预防和/或治疗新型冠状病毒的感染和/或由所述感染引起的疾病(例如,新型冠状病毒肺炎)。
10.111592595抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用
CN 28.08.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202010342471.6 Applicant 南京医科大学 Inventor 高威
本发明涉及抗新型冠状病毒SARS‑Cov‑2的中和性抗体及其应用。该抗体至少具有重链CDR1、重链CDR2、重链CDR3、轻链CDR1、轻链CDR2、轻链CDR3之一。该抗体可用于制备检测、预防、治疗COVID‑19的诊断试剂或诊断试剂盒、药物或药物组合物。本发明以噬菌体展示技术靶向SARS‑Cov‑2‑RBD与SARS‑Cov‑1‑RBD进行差异性抗体筛选,获得了抗新型冠状病毒SARS‑Cov‑2的中和性抗体,能够阻断SARS‑Cov‑2‑RBD与ACE2阳性细胞的结合,对SARS‑Cov‑2伪病毒具有显著的病毒中和作用,为COVID‑19的预防和治疗提供了有效的备选抗体药物。